Recursion Pharmaceuticals (RXRX) Operating Income (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted Operating Income of -$128.5 million for Q1 2026, down 18.62% on a QoQ basis from -$108.3 million in Q4 2025, and up 32.85% year-over-year from -$96.7 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) Operating Income (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Operating Income history runs 7 years deep, the most recent figure standing at -$128.5 million for Q1 2026.
- Quarterly Operating Income rose 32.85% year-over-year to -$128.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$585.3 million (down 1.96% YoY) and the FY2025 annual result came in at -$648.1 million, down 35.31% from the prior year.
- Operating Income was -$128.5 million for Q1 2026 at Recursion Pharmaceuticals, down from -$108.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$56.0 million in Q1 2022 and bottomed at -$191.4 million in Q1 2025.
- A 5-year average of -$108.9 million and a median of -$98.9 million in 2023 frame the typical range for Operating Income.
- Peak annual rise in Operating Income reached 41.05% in 2025, while the deepest fall reached 98.64% in 2025.
- Recursion Pharmaceuticals' Operating Income stood at -$61.0 million in 2022, then sank by 62.23% to -$98.9 million in 2023, then sank by 85.76% to -$183.8 million in 2024, then soared by 41.05% to -$108.3 million in 2025, then fell by 18.62% to -$128.5 million in 2026.
- Business Quant data shows RXRX's Operating Income at -$128.5 million in Q1 2026, -$108.3 million in Q4 2025, and -$172.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | -128.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.51 Mn |
| Dec 31, 2025 | -108.33 Mn |
| Sep 30, 2025 | -172.20 Mn |
| Jun 30, 2025 | -176.23 Mn |
| Mar 31, 2025 | -191.37 Mn |
| Dec 31, 2024 | -183.77 Mn |
| Sep 30, 2024 | -98.35 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Mar 31, 2024 | -96.34 Mn |
| Dec 31, 2023 | -98.93 Mn |
| Sep 30, 2023 | -99.55 Mn |
| Jun 30, 2023 | -81.72 Mn |
| Mar 31, 2023 | -69.87 Mn |
| Dec 31, 2022 | -60.98 Mn |
| Sep 30, 2022 | -62.57 Mn |
| Jun 30, 2022 | -66.19 Mn |
| Mar 31, 2022 | -55.98 Mn |
| Dec 31, 2021 | -64.96 Mn |
| Sep 30, 2021 | -46.40 Mn |
| Jun 30, 2021 | -40.93 Mn |